These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12783637)

  • 21. Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia.
    Bolli GB
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):13-20. PubMed ID: 19667675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin glargine: a new long-acting insulin product.
    Reinhart L; Panning CA
    Am J Health Syst Pharm; 2002 Apr; 59(7):643-9. PubMed ID: 11944604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term.
    Prescrire Int; 2006 Dec; 15(86):203-9. PubMed ID: 17165235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.
    McKeage K; Goa KL
    Treat Endocrinol; 2002; 1(1):55-8. PubMed ID: 15765621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin preparations with prolonged effect.
    Owens DR
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S5-14. PubMed ID: 21668337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of twice-daily injection with insulin glargine: a case report and review of the literature.
    Youssef D; El Abbassi A; Woodby G; Peiris AN
    Tenn Med; 2010 Feb; 103(2):42-3. PubMed ID: 20345066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin glargine: an updated review of its use in the management of diabetes mellitus.
    Dunn CJ; Plosker GL; Keating GM; McKeage K; Scott LJ
    Drugs; 2003; 63(16):1743-78. PubMed ID: 12904090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidiabetic agents.
    Francisco GE
    Prim Care; 1990 Sep; 17(3):499-519. PubMed ID: 2236334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic insulin analogs and their use in dogs and cats.
    Gilor C; Graves TK
    Vet Clin North Am Small Anim Pract; 2010 Mar; 40(2):297-307. PubMed ID: 20219490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The future of basal insulin supplementation.
    Simon AC; DeVries JH
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S103-8. PubMed ID: 21568722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medication of the month. Insulin glargine (Lantus)].
    Scheen AJ
    Rev Med Liege; 2004 Feb; 59(2):110-4. PubMed ID: 15112902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin formulations--a review.
    Gualandi-Signorini AM; Giorgi G
    Eur Rev Med Pharmacol Sci; 2001; 5(3):73-83. PubMed ID: 12004916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically engineered insulin analogs: diabetes in the new millenium.
    Vajo Z; Duckworth WC
    Pharmacol Rev; 2000 Mar; 52(1):1-9. PubMed ID: 10699152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive insulin therapy: Part II. Multicomponent insulin regimens.
    Hirsch IB; Herter CD
    Am Fam Physician; 1992 Jun; 45(6):2643-8. PubMed ID: 1595513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin glargine versus NPH insulin in patients with type 1 diabetes.
    Ratner R
    Drugs Today (Barc); 2003 Nov; 39(11):867-76. PubMed ID: 14702132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent trends of development of rapid-acting and long-acting human insulin analogues--its biological characteristics and clinical availability].
    Yokono K
    Nihon Rinsho; 2001 Nov; 59(11):2127-33. PubMed ID: 11712396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.